Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Vivatuxin + TACE in Advanced HCC
NCT02724267Completed
- Sponsor
- Eastern Hepatobiliary Surgery Hospital
- Start
- Nov 2012
- Primary completion
- Jun 2015
- Modality
- Monoclonal Antibodies
- Countries
- 1
01
Overview
Randomised trial of iodine-131-chTNT in hepatocellular carcinoma (HCC) (2 arms), sponsored by Eastern Hepatobiliary Surgery Hospital. Primary endpoint: Overall Survival at 3 years. Started Nov 2012; status: completed.
02
Drugs
iodine-131-chTNT
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on NCT02724267.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02724267.